liraglutide (Saxenda, generic) — Medica

Initial criteria

• age ≥ 18 years
• patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
• patient had at baseline BMI ≥ 30 kg/m2 OR (baseline BMI ≥ 27 kg/m2 AND ≥ 1 weight-related comorbidity: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease, polycystic ovarian syndrome, coronary artery disease)
• medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Reauthorization criteria

• age ≥ 18 years
• same BMI/comorbidity baseline criteria as for initial therapy
• patient has lost ≥ 4% of baseline body weight
• medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Approval duration

initial: 4 months; continuation: 1 year